Effects of tongxinluo capsule on cardiac ventricle remodeling after myocardial infarction: a multicentre clinical research
Chen, W.; Sun, X.; Wang, W.-j.; Fu, X.-d.; Fu, D.-y.; Zhou, J.-m.; Wu, Y.-l.
Zhonghua Yi Xue Za Zhi 88(32): 2271-2273
2008
ISSN/ISBN: 0376-2491 PMID: 19087677 Document Number: 618271
To investigate the effects of tongxinluo (TXL) capsule on cardiac ventricle remodeling after acute myocardial infarction (AMI). Seventy AMI patients were randomly divided into 2 equal groups: conventional therapy group treated with conventional Western therapy and TXL treatment group treated with TXL capsule for 6 weeks in addition to the conventional treatment. Cardiac color ultrasound was conducted before and 6 weeks after the treatment to examine the changes of ventricular structure, mass and function. Radioimmunoassay was used to detect the levels of angiotensin II (Ang II) and endothelin-1 (ET-1). Six weeks later, the left ventricular posterior wall thickness of end-diastolic (LVPWTD), left ventricular end-systolic dimension (LVESD), and left atrium dimension (LAD) of the TXL group were 0.93 cm +/- 0.09 cm, 3.71 cm +/- 0.19 cm, and 3.21 cm +/- 0.29 cm respectively, all lower than those before treatment (0.93 cm +/- 0.09 cm, 3.71 cm +/- 0.19 cm, and 3.21 cm +/- 0.29 cm respectively) and those of the conventional treatment group (0.95 cm +/- 0.08 cm, 3.62 cm +/- 0.46 cm, and 3.82 cm +/- 0.30 cm) (all P < 0.05), the ejection-fraction (EF) improvement rate of the TXL group was 63% +/- 7%, significantly higher than that before treatment (52% +/- 6%) and that of the conventional treatment group (59% +/- 8%, both P < 0.05). TXL capsule in addition to conventional therapy has a positive effect on the prognosis of AMI via reversing the ventricular remodeling, and improving cardiac function.